Related Experiment Videos
Antibody-enzyme conjugates for cancer therapy
1Centre for Applied Microbiology and Research, Porton Down, Salisbury, UK.
Journal of the National Cancer Institute
|February 21, 1996
Summary
Antibody-directed enzyme prodrug therapy (ADEPT) uses targeted enzymes to activate potent anticancer drugs specifically at tumor sites. Research is advancing ADEPT systems to overcome immunogenicity and improve future cancer treatments.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Antibody-directed enzyme prodrug therapy (ADEPT) utilizes antibody-enzyme conjugates to activate prodrugs at tumor sites.
- This approach enables the use of highly potent cytotoxic agents, such as nitrogen mustards, which are too toxic for conventional chemotherapy.
Purpose of the Study:
- To review the development and potential of ADEPT in cancer treatment.
- To address challenges like immunogenicity and explore future advancements in ADEPT systems.
Main Methods:
- Development of prodrugs for clinically used and novel anticancer agents.
- Construction of antibody-enzyme conjugates using various enzymes and monoclonal antibodies.
- Investigation of strategies to overcome immunogenicity, including immunosuppression and development of humanized systems.
Main Results:
- Preliminary studies validated the ADEPT technique, demonstrating its value in targeted drug delivery.
- Identified immunogenicity of non-human proteins as a key challenge in ADEPT.
Conclusions:
- ADEPT offers a promising strategy for targeted cancer therapy, allowing the use of highly potent drugs.
- Future research focuses on humanized antibody-enzyme systems and improved prodrugs to enhance ADEPT efficacy and safety.